Table 1 Importance of health-related variables for risk-sharing agreements
From: Implementation of risk-sharing contracts as perceived by Spanish hospital pharmacists
| Â | The hospital has only price-volume agreements | The hospital has payment-for-efficacy or efficiency (with or without price-volume) | ||||
|---|---|---|---|---|---|---|
HEALTH RELATED VARIABLES | Price-volume | Paying-for-efficacy | Payment-for-efficiency | Price-volume | Payment-for-efficacy | Payment-for-efficiency |
Treatment efficacy | 3 (2,9%) | 54 (52,9%) | 45 (44,1%) | 3 (9,4%) | 17 (53,1%) | 12 (37,5%) |
Treatment efficiency | 2 (1,9%) | 46 (45,1%) | 54 (52,9%) | 1 (3,7%) | 10 (37%) | 16 (59,2%) |
Duration of the treatment | 54 (48,6%) | 30 (27%) | 27 (24,3%) | 15 (50%) | 8 (26,7%) | 7 (23,3%) |
Uncertainty on treatment effectiveness | 17 (15%) | 52 (46%) | 44 (38,9%) | 4 (12,5%) | 15 (46,9%) | 13 (40,6%) |
Adverse events and toxicity | 13 (12,7%) | 51 (50%) | 38 (37,2%) | 3 (9,4%) | 17 (53,1%) | 12 (37,5%) |
Incremental safety versus the standard of care | 9 (8,9%) | 53 (52,5%) | 39 (38,6%) | 2 (7,1%) | 14 (50%) | 12 (42,8%) |
Size of target population | 56 (60,8%) | 20 (21,7%) | 16 (17,4%) | 15 (60%) | 6 (24%) | 4 (16%) |
Number of packages of medication per year | 56 (88,9%) | 4 (6,3%) | 3 (4,8%) | 16 (94,1%) | 1 (5,9%) | 0 (0%) |
Unitary cost per dose | 56 (59,6%) | 18 (19,1%) | 20 (21,2%) | 13 (50%) | 6 (23,1%) | 7 (26,9%) |
High budget impact of the treatment | 55 (74,3%) | 9 (12,2%) | 10 (13,5%) | 13 (50%) | 6 (23,1%) | 7 (26,9%) |
Rare disease | 30 (34,9%) | 44 (51,2%) | 12 (13,9%) | 10 (41,7%) | 10 (41,7%) | 4 (16,7%) |
Orphan drug | 30 (35,3%) | 43 (50,6%) | 12 (14,1%) | 11 (42,3%) | 11 (42,3%) | 4 (15,4%) |
First in class drug | 16 (23,9%) | 45 (67,1%) | 6 (8,9%) | 6 (26,1%) | 13 (56,5%) | 4 (17,4%) |
Previous experience of agreements with the laboratory | 23 (31,5%) | 44 (60,3%) | 6 (8,2%) | 13 (40,6%) | 13 (40,6%) | 6 (18,7%) |